Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4M1SG)

Drug Name
Clarithromycin Drug Info
Synonyms
Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
84029
ChEBI ID
CHEMBL1741
CAS Number
CAS 81103-11-9
TTD Drug ID
D0Z1ZM
VARIDT Drug ID
DR00713
INTEDE Drug ID
DR0336
ACDINA Drug ID
D00134

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Neutrophil extracellular trap formation 1.94 7.00e-2 101/189 (53.44%) PIK3R1;C5AR1;AQP9;...
Leishmaniasis 1.84 7.71e-2 67/77 (87.01%) HLA-DOB;FCGR2A;CYBA;...
Intestinal immune network for IgA production 1.81 7.47e-2 38/48 (79.17%) HLA-DOB;CD86;TGFB1;...
VEGF signaling pathway 1.75 1.33e-1 50/59 (84.75%) PIK3R1;CDC42;PRKCA;...
Platelet activation 1.73 1.23e-1 106/124 (85.48%) GNAS;PIK3R1;MYLK;...
Morphine addiction 1.69 1.52e-1 80/91 (87.91%) GNAS;ARRB2;GNB2;...
Nitrogen metabolism 1.68 1.38e-1 16/17 (94.12%) GLUL;CA2;CA12;...
Choline metabolism in cancer 1.66 1.37e-1 84/98 (85.71%) PIK3R1;CHPT1;PLPP1;...
Fc gamma R-mediated phagocytosis 1.65 1.32e-1 79/97 (81.44%) PIK3R1;MARCKS;CDC42;...
Type I diabetes mellitus 1.51 1.70e-1 38/43 (88.37%) HLA-DOB;CD86;HLA-DRA;...
Drug metabolism 1.51 1.65e-1 78/151 (51.66%) ADH5;NME4;ALDH3A1;...
Dopaminergic synapse 1.51 1.60e-1 115/132 (87.12%) GNAS;GRIA2;ARRB2;...
Tuberculosis 1.50 1.56e-1 159/180 (88.33%) CD14;HLA-DOB;RAB5C;...
Chagas disease 1.50 1.55e-1 93/102 (91.18%) GNAS;TGFBR2;PIK3R1;...
Chemokine signaling pathway 1.50 1.57e-1 163/192 (84.9%) PIK3R1;ARRB2;CXCL8;...
GnRH signaling pathway 1.50 1.55e-1 80/93 (86.02%) GNAS;MAP2K6;CDC42;...
Staphylococcus aureus infection 1.49 1.59e-1 72/95 (75.79%) C5AR1;HLA-DOB;CFI;...
Protein export 1.49 1.56e-1 17/23 (73.91%) SPCS1;OXA1L;SRPRB;...
Phospholipase D signaling pathway 1.49 1.53e-1 134/148 (90.54%) GNAS;PIK3R1;CXCL8;...
Vibrio cholerae infection 1.48 1.57e-1 44/50 (88%) GNAS;KDELR3;ATP6V0E2;...
Regulation of actin cytoskeleton 1.47 1.64e-1 185/218 (84.86%) PFN2;PIK3R1;MYLK;...
TNF signaling pathway 1.47 1.60e-1 103/112 (91.96%) MAP2K6;PIK3R1;JUNB;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.46 1.66e-1 9/11 (81.82%) NQO1;HPD;GGCX;...
Osteoclast differentiation 1.46 1.65e-1 117/127 (92.13%) TGFBR2;MAP2K6;PIK3R1;...
Human cytomegalovirus infection 1.45 1.69e-1 201/225 (89.33%) E2F2;GNAS;MAP2K6;...
Glutathione metabolism 1.45 1.72e-1 43/57 (75.44%) GSTP1;PGD;G6PD;...
Melanogenesis 1.45 1.69e-1 74/101 (73.27%) GNAS;PLCB1;TYRP1;...
Tryptophan metabolism 1.44 1.71e-1 35/42 (83.33%) KYNU;KMO;DLST;...
Oxytocin signaling pathway 1.44 1.68e-1 128/154 (83.12%) GNAS;MYLK;RCAN1;...
Chemical carcinogenesis 1.44 1.66e-1 186/281 (66.19%) GNAS;PIK3R1;UGT2B28;...
Aldosterone synthesis and secretion -1.04 7.13e-1 85/98 (86.73%) CYP11B2;CALML5;PRKD3;...
p53 signaling pathway -1.04 7.23e-1 63/73 (86.3%) ATR;SFN;CD82;...
ECM-receptor interaction -1.04 7.43e-1 80/88 (90.91%) LAMB2;ITGA8;ITGAV;...
Steroid hormone biosynthesis -1.05 7.39e-1 43/61 (70.49%) HSD17B7;HSD3B2;CYP3A7;...
alpha-Linolenic acid metabolism -1.06 7.46e-1 17/25 (68%) PLA2G5;PLA2G12A;PLA2G4C;...
Galactose metabolism -1.06 7.48e-1 26/31 (83.87%) GALT;GLA;PFKM;...
TGF-beta signaling pathway -1.08 7.37e-1 81/94 (86.17%) BMPR1A;AMHR2;LTBP1;...
Glycolysis / Gluconeogenesis -1.12 6.87e-1 56/67 (83.58%) BPGM;FBP1;PGAM1;...
Estrogen signaling pathway -1.13 6.91e-1 119/137 (86.86%) CREB5;HSPA8;PLCB4;...
Taurine and hypotaurine metabolism -1.14 6.68e-1 8/11 (72.73%) CDO1;ADO
Measles -1.14 6.88e-1 133/139 (95.68%) STAT1;IFNAR1;CASP3;...
Selenocompound metabolism -1.15 7.10e-1 11/17 (64.71%) MTR;PAPSS2;CTH
Caffeine metabolism -1.15 7.31e-1 5/6 (83.33%) CYP2A6;NAT1
Amino sugar and nucleotide sugar metabolism -1.17 6.99e-1 38/48 (79.17%) UAP1;GALT;CMAS;...
Arginine biosynthesis -1.18 7.13e-1 17/22 (77.27%) ARG2;CPS1;GLS2;...
Glycosphingolipid biosynthesis -1.19 7.31e-1 37/57 (64.91%) A4GALT;FUT6;B3GALT4;...
Sulfur metabolism -1.20 7.31e-1 9/10 (90%) TST;PAPSS2
Fatty acid elongation -1.26 5.42e-1 19/27 (70.37%) PPT1;HADH;HADHB;...
SNARE interactions in vesicular transport -1.27 5.42e-1 19/33 (57.58%) GOSR1;STX1A;STX6;...
Protein digestion and absorption -1.31 4.64e-1 78/103 (75.73%) SLC3A1;KCNK5;FXYD2;...
Arginine and proline metabolism -1.32 4.55e-1 39/50 (78%) SMOX;CKM;ARG2;...
Ovarian steroidogenesis -1.39 3.17e-1 41/51 (80.39%) LHCGR;IGF1R;CYP17A1;...
ABC transporters -1.43 2.74e-1 37/45 (82.22%) ABCC5;ABCB11;ABCA7;...
Glycine, serine and threonine metabolism -1.44 2.77e-1 31/40 (77.5%) PIPOX;SHMT1;AOC3;...
Nicotinate and nicotinamide metabolism -1.48 2.46e-1 25/35 (71.43%) SIRT3;PNP;ENPP1;...
Primary immunodeficiency -1.48 2.87e-1 33/38 (86.84%) AICDA;ADA;BLNK;...
Glycosaminoglycan biosynthesis -1.49 3.45e-1 40/58 (68.97%) HS3ST2;EXT1;EXT2;...
Cysteine and methionine metabolism -1.57 2.52e-1 43/50 (86%) BHMT2;CDO1;GOT1;...
Steroid biosynthesis -1.74 8.34e-2 19/20 (95%) EBP;SOAT2;HSD17B7;...
Ribosome biogenesis in eukaryotes -1.76 1.34e-1 52/108 (48.15%) CSNK2A1;FBL;GNL2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 4uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H